valproic acid has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) has been used for epilepsy treatment since the 1970s." | 3.76 | Valproic acid in the complex therapy of malignant tumors. ( Eckschlager, T; Hrabeta, J; Hrebackova, J, 2010) |
| "A series of 8 patients with chronic myeloid leukemia (CML) refractory to imatinib mesylate with no access to second-generation tyrosine kinase inhibitors were treated with hydralazine and valproate in a compassionate manner." | 1.38 | Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. ( Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shvachko, LP | 1 |
| Zavelevich, MP | 1 |
| Gluzman, DF | 1 |
| Kravchuk, IV | 1 |
| Telegeev, GD | 1 |
| Wang, W | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Yang, X | 1 |
| He, Y | 1 |
| Li, T | 1 |
| Ren, F | 1 |
| Lin, R | 1 |
| Kircher, B | 1 |
| Schumacher, P | 1 |
| Petzer, A | 1 |
| Hoflehner, E | 1 |
| Haun, M | 1 |
| Wolf, AM | 1 |
| Nachbaur, D | 1 |
| Gastl, G | 1 |
| Hrebackova, J | 1 |
| Hrabeta, J | 1 |
| Eckschlager, T | 1 |
| Buchi, F | 1 |
| Pastorelli, R | 1 |
| Ferrari, G | 1 |
| Spinelli, E | 1 |
| Gozzini, A | 1 |
| Sassolini, F | 1 |
| Bosi, A | 1 |
| Tombaccini, D | 1 |
| Santini, V | 1 |
| Zhang, XZ | 1 |
| Yin, AH | 1 |
| Zhu, XY | 1 |
| Ding, Q | 1 |
| Wang, CH | 1 |
| Chen, YX | 1 |
| Cervera, E | 1 |
| Candelaria, M | 1 |
| López-Navarro, O | 1 |
| Labardini, J | 1 |
| Gonzalez-Fierro, A | 1 |
| Taja-Chayeb, L | 1 |
| Cortes, J | 1 |
| Gordillo-Bastidas, D | 1 |
| Dueñas-González, A | 1 |
| Morotti, A | 1 |
| Cilloni, D | 1 |
| Messa, F | 1 |
| Arruga, F | 1 |
| Defilippi, I | 1 |
| Carturan, S | 1 |
| Catalano, R | 1 |
| Rosso, V | 1 |
| Chiarenza, A | 1 |
| Pilatrino, C | 1 |
| Guerrasio, A | 1 |
| Taulli, R | 1 |
| Bracco, E | 1 |
| Pautasso, M | 1 |
| Baraban, D | 1 |
| Gottardi, E | 1 |
| Saglio, G | 1 |
| Cheng, H | 1 |
| Liu, Z | 1 |
| Blum, W | 1 |
| Byrd, JC | 1 |
| Klisovic, R | 1 |
| Grever, MR | 1 |
| Marcucci, G | 1 |
| Chan, KK | 1 |
9 other studies available for valproic acid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Vitamin Е activates expression of С/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells.
Topics: Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-alpha; Cell Line, Tumor; Fusion Proteins, bcr- | 2018 |
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Dru | 2015 |
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Case-Control Studies; Cell Line, Tumor; | 2009 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; | 2010 |
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.
Topics: Acetylation; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm | 2011 |
Using an exon microarray to identify a global profile of gene expression and alternative splicing in K562 cells exposed to sodium valproate.
Topics: Alternative Splicing; Antineoplastic Agents; Apoptosis; Cell Survival; Exons; Flow Cytometry; Gene E | 2012 |
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Fo | 2012 |
Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Interactions; Drug Resistance, Neoplasm; Enzyme I | 2006 |
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Fatty Acids, Monounsaturated; Humans; Leukemia, Myelogenous, C | 2007 |